ClinicalTrials.gg
CompletedNCT03325712Updated Sep 7, 2022Results posted

This Study in Healthy Men Tests How Different Doses of BI 705564 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How BI 705564 Affects the Way the Body Breaks Down Midazolam

A Phase 1 interventional study of BI 705564 and Placebo in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-07.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

The primary objective of this trial is to investigate safety and tolerability of BI 705564 in healthy male subjects, following oral administration of multiple rising doses.

Secondary objectives are the exploration of the pharmacokinetics, including dose proportionality and investigation of linearity.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Dose Groups (DGs)1 to 5: Healthy male subjects according to the assessment of the investigator, based on a complete medical history, a physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead (ECG), and clinical laboratory tests;
  • DG 8, only: Otherwise healthy male subjects (as defined for DGs 1 to 5) with a history (of at least 1 year) of IgE-mediated, perennial allergies, predominantly to (house) dust mite (dermatophagoides pteronyssinus or dermatophagoides farina) as documented by a positive Skin prick test (SPT)(largest diameter of wheal at screening > 5 mm)

    • Age of 18 to 50 years (incl.)
    • Body Max Index () of 18.5 to 29.9 kg/m2 (incl.)
    • Signed and dated written prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation

Exclusion criteria

Exclusion Criteria:

  • Any finding in the medical examination (including Blood Pressure (BP), Pulse Rate (PR) or (ECG)) is deviating from normal and judged as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 bpm
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease judged as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Cholecystectomy and/ or surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy and simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizure or stroke), and other relevant neurological or psychiatric disorders
  • History of relevant orthostatic hypotension, fainting spells, or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy or (including allergy to the trial medication or its )
  • Use of drugs within 30 days prior to administration of trial medication, if that might reasonably influence the results of the trial (incl. /QTc interval prolongation)
  • Participation in another trial where an drug has been administered within 60 days prior to planned administration of trial medication, or current participation in another trial involving administration of investigational drug.
  • Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
  • Inability to refrain from smoking on specified trial days
  • Alcohol abuse (consumption of more than 30 g per day)
  • Drug abuse or positive drug screening
  • Blood donation of more than 100 mL within 30 days prior to the administration of trial medication or intended donation during the trial
  • Intention to perform excessive physical activities within one week prior to the administration of trial medication or during the trial
  • Inability to comply with dietary regimen of the trial site
  • A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are repeatedly greater than 450 ms in males) or any other relevant Electrocardiogram (ECG) finding at screening
  • A history of additional risk factors for Torsades de Pointes (such as heart failure, hypokalemia, or family history of Long QT Syndrome)
  • Subject is assessed as unsuitable for inclusion by the investigator, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study

In addition, the following trial-specific exclusion criteria apply:

  • Male subject with women of child bearing potential () partner who is unwilling to use male (condom or sexual abstinence) from the first administration of trial medication until 30 days after last administration of trial medication
  • Subjects who, in the investigator's judgement, are perceived as having an increased risk of bleeding, e.g. history of haemorrhagic disorders, clinical relevant petechial bleeding, occult blood in faeces, haematuria in repeated urine tests, trauma or surgery within the last month planned surgery during trial participation, history of arteriovenous malformation or aneurysm, history of gastroduodenal ulcer disease or gastrointestinal haemorrhage, history of intracranial, intraocular, spinal, retroperitoneal, or atraumatic intraarticular bleeding, use of drugs that may interfere with haemostasis during trial conduct (e.g. acetylic salicylic acid or other non-steroidal anti-inflammatory drugs)
  • Repeated counts below 100 cells/nL at screening
  • Bleeding times (to monitor platelet function) above reference range at screening
  • Repeated absolute B cell (CD19+) counts below 40/μL at screening
  • Serum potassium below normal range at screening
  • A history or current clinical signs of acute pancreatitis
  • Further exclusion criteria apply.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Dose group 1: BI 705564 10 mg

    Drug: BI 705564

  • Experimental
    Dose group 2: BI 705564 20 mg

    Drug: BI 705564 · Drug: Midazolam

  • Experimental
    Dose group 3: BI 705564 40 mg

    Drug: BI 705564 · Drug: Midazolam

  • Experimental
    Dose group 5: BI 705564 60 mg

    Drug: BI 705564 · Drug: Midazolam

  • Experimental
    Dose group 4: BI 705564 80 mg

    Drug: BI 705564 · Drug: Midazolam

  • Placebo comparator
    Placebo matching BI 705564

    Drug: Placebo · Drug: Midazolam

  • Experimental
    Dose group 8: BI 705564 40 mg - SPT

    SPT stands for skin prick test.

    Drug: BI 705564

  • Placebo comparator
    Placebo matching BI 705564 - SPT

    SPT stands for skin prick test.

    Drug: Placebo

Interventions

  • Film-coated tablet

  • DrugPlacebo

    Film-coated tablet

  • Solution for injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Drug-related Adverse Events

    Percentage of participants with drug-related adverse events is reported.

    Time frame: From first drug administration until 10 days after last drug administration, up to 27 days (for dose groups 1 to 5 and "Placebo Matching BI 705564") or up to 37 days (for dose group 8 and "Placebo Matching BI 705564 - SPT").

Secondary outcomes

  1. Area Under the Concentration-time Curve of BI 705564 in Plasma Over a Uniform Dosing Interval τ After Administration of the First Dose (AUCτ,1)

    Area under the concentration-time curve of BI 705564 in plasma over a uniform dosing interval τ after administration of the first dose of BI 705564 (AUCτ,1) is reported. Here AUCτ,1 = AUC0-24.

    Time frame: 1 hour(s) (h) prior drug administration and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h after first BI 705564 dose (for dose groups 1 to 5); 1.5 h prior drug administration and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 23 h after first BI 705564 dose (for dose group 8).

  2. Maximum Measured Concentration of BI 705564 in Plasma (Cmax) After the Administration of the First Dose

    Maximum measured concentration of BI 705564 in plasma (Cmax) after the administration of the first dose of BI 705564 is reported.

    Time frame: 1 hour(s) (h) prior drug administration and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h after first BI 705564 dose (for dose groups 1 to 5); 1.5 h prior drug administration and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 23 h after first BI 705564 dose (for dose group 8).

  3. Area Under the Concentration-time Curve of BI 705564 in Plasma at Steady State Over a Uniform Dosing Interval τ (AUCτ,ss) After the Administration of the Last Dose

    Area under the concentration-time curve of BI 705564 in plasma at steady state over a uniform dosing interval τ (AUCτ,ss) after the administration of the last dose of BI 705564 is reported. As per the protocol, day is counted as "Day 1 = 0:00".

    Time frame: 1 h before last dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h after last BI 705564 dose on Day 17 (for dose groups 1 to 5); 1.5 h before last dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 23 h after last BI 705564 dose on Day 28 (for dose group 8).

  4. Maximum Measured Concentration of BI 705564 in Plasma at Steady State Over a Uniform Dosing Interval τ (Cmax,ss) After the Administration of the Last Dose

    Maximum measured concentration of BI 705564 in plasma at steady state over a uniform dosing interval τ (Cmax,ss) after the administration of the last dose. As per the protocol, day is counted as "Day 1 = 0:00".

    Time frame: 1 h before last dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h after last BI 705564 dose on Day 17 (for dose groups 1 to 5); 1.5 h before last dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 23 h after last BI 705564 dose on Day 28 (for dose group 8).

  5. Area Under the Concentration-time Curve of Midazolam in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) After the First and Last Dose

    Area under the concentration-time curve of Midazolam in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) after the first and last dose for "Placebo Matching BI 705564" group and for dose groups 2 to 5 is reported.

    Time frame: 1.5 h prior midazolam administration and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6 and 8 h after first midazolam dose on Day -1 and 1h prior midazolam administration and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6 and 8 h after last midazolam dose on Day 17.

  6. Maximum Measured Concentration of Midazolam in Plasma (Cmax) After the First and Last Dose

    Maximum measured concentration of Midazolam in plasma (Cmax) after the first and last dose for "Placebo Matching BI 705564" group and for dose groups 2 to 5 is reported.

    Time frame: 1.5 h prior midazolam administration and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6 and 8 h after first midazolam dose on Day -1 and 1h prior midazolam administration and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6 and 8 h after last midazolam dose on Day 17.

07

Results

Posted Jul 11, 2022

Participant flow

The evaluation of multiple rising dose (MRD) of BI 705564 was designed as randomised, placebo-controlled, double-blind and parallel-group design and the evaluation of midazolam interaction was designed as nested, open-label, fixed-sequence, intra-individual comparison in healthy male participants.

Participant flow — Overall Study
MilestonePlacebo Matching BI 705564Placebo Matching BI 705564 - SPTDose Group 1: BI 705564 10 mgDose Group 2: BI 705564 20 mgDose Group 3: BI 705564 40 mgDose Group 5: BI 705564 60 mgDose Group 4: BI 705564 80 mgDose Group 8: BI 705564 40 mg - SPT
Started102888888
Completed102886888
Not completed00002000
Withdrew: Protocol violation00001000
Withdrew: Adverse event00001000

Outcome measures

PrimaryPercentage of Participants With Drug-related Adverse Events

Percentage of participants with drug-related adverse events is reported.

Time frame:
From first drug administration until 10 days after last drug administration, up to 27 days (for dose groups 1 to 5 and "Placebo Matching BI 705564") or up to 37 days (for dose group 8 and "Placebo Matching BI 705564 - SPT").
Reported as:
Number · Percentage of participants (%)
Percentage of Participants With Drug-related Adverse Events
Percentage of participants (%)Placebo Matching BI 705564Placebo Matching BI 705564 - SPTDose Group 1: BI 705564 10 mgDose Group 2: BI 705564 20 mgDose Group 3: BI 705564 40 mgDose Group 5: BI 705564 60 mgDose Group 4: BI 705564 80 mgDose Group 8: BI 705564 40 mg - SPT
Percentage of Participants With Drug-related Adverse Events20.050.012.50.050.050.012.575.0
SecondaryArea Under the Concentration-time Curve of BI 705564 in Plasma Over a Uniform Dosing Interval τ After Administration of the First Dose (AUCτ,1)

Area under the concentration-time curve of BI 705564 in plasma over a uniform dosing interval τ after administration of the first dose of BI 705564 (AUCτ,1) is reported. Here AUCτ,1 = AUC0-24.

Time frame:
1 hour(s) (h) prior drug administration and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h after first BI 705564 dose (for dose groups 1 to 5); 1.5 h prior drug administration and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 23 h after first BI 705564 dose (for dose group 8).
Reported as:
Geometric mean · nanomole*hour/liter (nmol*h/L)
Area Under the Concentration-time Curve of BI 705564 in Plasma Over a Uniform Dosing Interval τ After Administration of the First Dose (AUCτ,1)
nanomole*hour/liter (nmol*h/L)Dose Group 1: BI 705564 10 mgDose Group 2: BI 705564 20 mgDose Group 3: BI 705564 40 mgDose Group 5: BI 705564 60 mgDose Group 4: BI 705564 80 mgDose Group 8: BI 705564 40 mg - SPT
Area Under the Concentration-time Curve of BI 705564 in Plasma Over a Uniform Dosing Interval τ After Administration of the First Dose (AUCτ,1)42.1 ± 40.670.8 ± 31.7131.0 ± 22.4168.0 ± 40.1238.0 ± 46.6120.0 ± 33.9
Statistical analysis
  • Dose Group 1: BI 705564 10 mg vs Dose Group 2: BI 705564 20 mg vs Dose Group 3: BI 705564 40 mg vs Dose Group 5: BI 705564 60 mg vs Dose Group 4: BI 705564 80 mg · Slope: 0.8188 · 90% CI 0.6966 to 0.9410Based on the estimate for slope parameter (β), a 2-sided 90% CI for the slope was computed. Perfect dose proportionality would correspond to a slope of 1. Standard error of mean is standard error of slope.
SecondaryMaximum Measured Concentration of BI 705564 in Plasma (Cmax) After the Administration of the First Dose

Maximum measured concentration of BI 705564 in plasma (Cmax) after the administration of the first dose of BI 705564 is reported.

Time frame:
1 hour(s) (h) prior drug administration and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h after first BI 705564 dose (for dose groups 1 to 5); 1.5 h prior drug administration and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 23 h after first BI 705564 dose (for dose group 8).
Reported as:
Geometric mean · nanomole/Liter (nmol/L)
Maximum Measured Concentration of BI 705564 in Plasma (Cmax) After the Administration of the First Dose
nanomole/Liter (nmol/L)Dose Group 1: BI 705564 10 mgDose Group 2: BI 705564 20 mgDose Group 3: BI 705564 40 mgDose Group 5: BI 705564 60 mgDose Group 4: BI 705564 80 mgDose Group 8: BI 705564 40 mg - SPT
Maximum Measured Concentration of BI 705564 in Plasma (Cmax) After the Administration of the First Dose11.4 ± 42.218.8 ± 38.236.5 ± 17.841.0 ± 28.158.1 ± 54.431.7 ± 35.2
Statistical analysis
  • Dose Group 1: BI 705564 10 mg vs Dose Group 2: BI 705564 20 mg vs Dose Group 3: BI 705564 40 mg vs Dose Group 5: BI 705564 60 mg vs Dose Group 4: BI 705564 80 mg · Slope: 0.7708 · 90% CI 0.6449 to 0.8967Based on the estimate for slope parameter (β), a 2-sided 90% CI for the slope was computed. Perfect dose proportionality would correspond to a slope of 1. Standard error of mean is standard error of slope.
SecondaryArea Under the Concentration-time Curve of BI 705564 in Plasma at Steady State Over a Uniform Dosing Interval τ (AUCτ,ss) After the Administration of the Last Dose

Area under the concentration-time curve of BI 705564 in plasma at steady state over a uniform dosing interval τ (AUCτ,ss) after the administration of the last dose of BI 705564 is reported. As per the protocol, day is counted as "Day 1 = 0:00".

Time frame:
1 h before last dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h after last BI 705564 dose on Day 17 (for dose groups 1 to 5); 1.5 h before last dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 23 h after last BI 705564 dose on Day 28 (for dose group 8).
Reported as:
Geometric mean · nanomole *hour/liter (nmol*h/L)
Area Under the Concentration-time Curve of BI 705564 in Plasma at Steady State Over a Uniform Dosing Interval τ (AUCτ,ss) After the Administration of the Last Dose
nanomole *hour/liter (nmol*h/L)Dose Group 1: BI 705564 10 mgDose Group 2: BI 705564 20 mgDose Group 3: BI 705564 40 mgDose Group 5: BI 705564 60 mgDose Group 4: BI 705564 80 mgDose Group 8: BI 705564 40 mg - SPT
Area Under the Concentration-time Curve of BI 705564 in Plasma at Steady State Over a Uniform Dosing Interval τ (AUCτ,ss) After the Administration of the Last Dose45.9 ± 34.284.8 ± 25.9164.0 ± 34.3170.0 ± 62.1204.0 ± 179.0138.0 ± 32.1
Statistical analysis
  • Dose Group 1: BI 705564 10 mg vs Dose Group 2: BI 705564 20 mg vs Dose Group 3: BI 705564 40 mg vs Dose Group 5: BI 705564 60 mg vs Dose Group 4: BI 705564 80 mg · Slope: 0.7167 · 90% CI 0.4922 to 0.9412Based on the estimate for slope parameter (β), a 2-sided 90% CI for the slope was computed. Perfect dose proportionality would correspond to a slope of 1. Standard error of mean is standard error of slope.
SecondaryMaximum Measured Concentration of BI 705564 in Plasma at Steady State Over a Uniform Dosing Interval τ (Cmax,ss) After the Administration of the Last Dose

Maximum measured concentration of BI 705564 in plasma at steady state over a uniform dosing interval τ (Cmax,ss) after the administration of the last dose. As per the protocol, day is counted as "Day 1 = 0:00".

Time frame:
1 h before last dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h after last BI 705564 dose on Day 17 (for dose groups 1 to 5); 1.5 h before last dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 23 h after last BI 705564 dose on Day 28 (for dose group 8).
Reported as:
Geometric mean · nanomole/Liter (nmol/L)
Maximum Measured Concentration of BI 705564 in Plasma at Steady State Over a Uniform Dosing Interval τ (Cmax,ss) After the Administration of the Last Dose
nanomole/Liter (nmol/L)Dose Group 1: BI 705564 10 mgDose Group 2: BI 705564 20 mgDose Group 3: BI 705564 40 mgDose Group 5: BI 705564 60 mgDose Group 4: BI 705564 80 mgDose Group 8: BI 705564 40 mg - SPT
Maximum Measured Concentration of BI 705564 in Plasma at Steady State Over a Uniform Dosing Interval τ (Cmax,ss) After the Administration of the Last Dose13.3 ± 29.419.8 ± 23.741.8 ± 21.443.4 ± 57.252.6 ± 201.039.2 ± 28.3
Statistical analysis
  • Dose Group 1: BI 705564 10 mg vs Dose Group 2: BI 705564 20 mg vs Dose Group 3: BI 705564 40 mg vs Dose Group 5: BI 705564 60 mg vs Dose Group 4: BI 705564 80 mg · Slope: 0.6825 · 90% CI 0.4556 to 0.9094Based on the estimate for slope parameter (β), a 2-sided 90% CI for the slope was computed. Perfect dose proportionality would correspond to a slope of 1. Standard error of mean is standard error of slope.
SecondaryArea Under the Concentration-time Curve of Midazolam in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) After the First and Last Dose

Area under the concentration-time curve of Midazolam in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) after the first and last dose for "Placebo Matching BI 705564" group and for dose groups 2 to 5 is reported.

Time frame:
1.5 h prior midazolam administration and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6 and 8 h after first midazolam dose on Day -1 and 1h prior midazolam administration and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6 and 8 h after last midazolam dose on Day 17.
Reported as:
Geometric least squares mean · picomole*hour/Liter (pmol*h/L)
Area Under the Concentration-time Curve of Midazolam in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) After the First and Last Dose
picomole*hour/Liter (pmol*h/L)Placebo Matching BI 705564Dose Group 2: BI 705564 20 mgDose Group 3: BI 705564 40 mgDose Group 5: BI 705564 60 mgDose Group 4: BI 705564 80 mg
After last dose: Midazolam + BI705564 or Midazolam + Placebo (Treatment (T))4478.58 ± NA3463.24 ± NA4812.45 ± NA3458.32 ± NA3759.20 ± NA
After first dose: Midazolam alone (Reference (R))4356.03 ± NA3721.70 ± NA4382.24 ± NA3191.16 ± NA3445.42 ± NA
Statistical analysis
  • Placebo Matching BI 705564 · Ratio (t/r): 102.81 · 90% CI 87.18 to 121.25The effect of BI 705564 on midazolam is estimated by the ratio of the geometric mean (T/R) and confidence interval (CI). CI is calculated based on the residual error from ANOVA.
  • Dose Group 2: BI 705564 20 mg · Ratio (t/r): 93.06 · 90% CI 79.94 to 108.32The effect of BI 705564 on midazolam is estimated by the ratio of the geometric mean (T/R) and confidence interval (CI). CI is calculated based on the residual error from ANOVA.
  • Dose Group 3: BI 705564 40 mg · Ratio (t/r): 109.82 · 90% CI 103.59 to 116.42The effect of BI 705564 on midazolam is estimated by the ratio of the geometric mean (T/R) and confidence interval (CI). CI is calculated based on the residual error from ANOVA.
  • Dose Group 5: BI 705564 60 mg · Ratio ( t/r): 108.37 · 90% CI 92.00 to 127.66The effect of BI 705564 on midazolam is estimated by the ratio of the geometric mean (T/R) and confidence interval (CI). CI is calculated based on the residual error from ANOVA.
  • Dose Group 4: BI 705564 80 mg · Ratio (t/r): 109.11 · 90% CI 92.43 to 128.79The effect of BI 705564 on midazolam is estimated by the ratio of the geometric mean (T/R) and confidence interval (CI). CI is calculated based on the residual error from ANOVA.
SecondaryMaximum Measured Concentration of Midazolam in Plasma (Cmax) After the First and Last Dose

Maximum measured concentration of Midazolam in plasma (Cmax) after the first and last dose for "Placebo Matching BI 705564" group and for dose groups 2 to 5 is reported.

Time frame:
1.5 h prior midazolam administration and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6 and 8 h after first midazolam dose on Day -1 and 1h prior midazolam administration and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6 and 8 h after last midazolam dose on Day 17.
Reported as:
Geometric least squares mean · picomole/Liter (pmol/L)
Maximum Measured Concentration of Midazolam in Plasma (Cmax) After the First and Last Dose
picomole/Liter (pmol/L)Placebo Matching BI 705564Dose Group 2: BI 705564 20 mgDose Group 3: BI 705564 40 mgDose Group 5: BI 705564 60 mgDose Group 4: BI 705564 80 mg
After last dose: Midazolam +BI 705564 or Midazolam +Placebo (Treatment (T))1197.89 ± NA1040.42 ± NA1255.36 ± NA984.14 ± NA1058.32 ± NA
After first dose: Midazolam alone (Reference (R))1196.63 ± NA1232.26 ± NA1147.40 ± NA1031.18 ± NA1175.41 ± NA
Statistical analysis
  • Placebo Matching BI 705564 · Ratio (t/r): 100.10 · 90% CI 83.99 to 119.31The effect of BI 705564 on midazolam is estimated by the ratio of the geometric mean (T/R) and confidence interval (CI). CI is calculated based on the residual error from ANOVA.
  • Dose Group 2: BI 705564 20 mg · Ratio (t/r): 84.43 · 90% CI 72.29 to 98.62The effect of BI 705564 on midazolam is estimated by the ratio of the geometric mean (T/R) and confidence interval (CI). CI is calculated based on the residual error from ANOVA.
  • Dose Group 3: BI 705564 40 mg · Ratio (t/r): 109.41 · 90% CI 94.34 to 126.88The effect of BI 705564 on midazolam is estimated by the ratio of the geometric mean (T/R) and confidence interval (CI). CI is calculated based on the residual error from ANOVA.
  • Dose Group 5: BI 705564 60 mg · Ratio (t/r): 95.44 · 90% CI 79.75 to 114.21The effect of BI 705564 on midazolam is estimated by the ratio of the geometric mean (T/R) and confidence interval (CI). CI is calculated based on the residual error from ANOVA.
  • Dose Group 4: BI 705564 80 mg · Ratio (t/r): 90.04 · 90% CI 70.75 to 114.59The effect of BI 705564 on midazolam is estimated by the ratio of the geometric mean (T/R) and confidence interval (CI). CI is calculated based on the residual error from ANOVA.

Adverse events

Collected over From first drug administration until 10 days after last drug administration, up to 27 days (for dose groups 1 to 5 and "Placebo Matching BI 705564" ) or up to 37 days (for dose group 8 and "Placebo Matching BI 705564 - SPT").. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Matching BI 7055640/10 (0%)0/10 (0%)5/10 (50%)
Placebo Matching BI 705564 - SPT0/2 (0%)0/2 (0%)2/2 (100%)
Dose Group 1: BI 705564 10 mg0/8 (0%)0/8 (0%)3/8 (37.5%)
Dose Group 2: BI 705564 20 mg0/8 (0%)0/8 (0%)2/8 (25%)
Dose Group 3: BI 705564 40 mg0/8 (0%)0/8 (0%)4/8 (50%)
Dose Group 5: BI 705564 60 mg0/8 (0%)0/8 (0%)5/8 (62.5%)
Dose Group 4: BI 705564 80 mg0/8 (0%)0/8 (0%)2/8 (25%)
Dose Group 8: BI 705564 40 mg - SPT0/8 (0%)0/8 (0%)7/8 (87.5%)
Most frequent other events
Showing 10 of 38
Most frequent other events
EventPlacebo Matching BI 705564Placebo Matching BI 705564 - SPTDose Group 1: BI 705564 10 mgDose Group 2: BI 705564 20 mgDose Group 3: BI 705564 40 mgDose Group 5: BI 705564 60 mgDose Group 4: BI 705564 80 mgDose Group 8: BI 705564 40 mg - SPT
PalpitationsCardiac disorders0/101/20/80/80/80/80/80/8
FatigueGeneral disorders1/101/20/80/80/80/81/82/8
NasopharyngitisInfections and infestations1/101/20/80/80/80/80/82/8
ArthralgiaMusculoskeletal and connective tissue disorders1/101/20/80/80/80/80/80/8
Back painMusculoskeletal and connective tissue disorders0/101/20/80/81/80/80/80/8
Limb discomfortMusculoskeletal and connective tissue disorders0/101/20/80/80/80/80/80/8
Musculoskeletal discomfortMusculoskeletal and connective tissue disorders0/101/20/80/80/80/80/80/8
Pain in extremityMusculoskeletal and connective tissue disorders0/101/20/80/80/80/80/80/8
Spinal painMusculoskeletal and connective tissue disorders0/101/20/80/80/80/80/80/8
HeadacheNervous system disorders0/101/22/80/81/80/80/84/8

Baseline characteristics

Treated Set (TS): This subject set includes all subjects who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.

Age, Continuous
Age, Continuous(Years)Placebo Matching BI 705564Placebo Matching BI 705564 - SPTDose Group 1: BI 705564 10 mgDose Group 2: BI 705564 20 mgDose Group 3: BI 705564 40 mgDose Group 5: BI 705564 60 mgDose Group 4: BI 705564 80 mgDose Group 8: BI 705564 40 mg - SPTTotal
Mean40.1 ± 8.233.0 ± 2.834.8 ± 9.644.0 ± 5.732.3 ± 9.138.4 ± 8.340.5 ± 10.228.5 ± 10.736.9 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Matching BI 705564Placebo Matching BI 705564 - SPTDose Group 1: BI 705564 10 mgDose Group 2: BI 705564 20 mgDose Group 3: BI 705564 40 mgDose Group 5: BI 705564 60 mgDose Group 4: BI 705564 80 mgDose Group 8: BI 705564 40 mg - SPTTotal
Female000000000
Male10288888860
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Matching BI 705564Placebo Matching BI 705564 - SPTDose Group 1: BI 705564 10 mgDose Group 2: BI 705564 20 mgDose Group 3: BI 705564 40 mgDose Group 5: BI 705564 60 mgDose Group 4: BI 705564 80 mgDose Group 8: BI 705564 40 mg - SPTTotal
Hispanic or Latino000000000
Not Hispanic or Latino10288888860
Unknown or Not Reported000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Matching BI 705564Placebo Matching BI 705564 - SPTDose Group 1: BI 705564 10 mgDose Group 2: BI 705564 20 mgDose Group 3: BI 705564 40 mgDose Group 5: BI 705564 60 mgDose Group 4: BI 705564 80 mgDose Group 8: BI 705564 40 mg - SPTTotal
American Indian or Alaska Native000000000
Asian000000011
Native Hawaiian or Other Pacific Islander000000000
Black or African American000001102
White10178877755
More than one race011000002
Unknown or Not Reported000000000
08

Study locations

1 site
  • CRS Clinical Research Services Mannheim GmbH
    Mannheim, 68167, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Nov 2018, 12 months.

Results were first posted in Jul 2022, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2017
First posted
Oct 30, 2017
StartActual
Nov 17, 2017
Primary completionActual
Nov 26, 2018
CompletionActual
Nov 26, 2018
Results first posted
Jul 11, 2022
Last update
Sep 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03325712
Responsible party
Sponsor
First posted
Oct 30, 2017
Start date
Nov 17, 2017
Primary completion
Nov 26, 2018
Completion
Nov 26, 2018
Results posted
Jul 11, 2022
Last update
Sep 7, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BI 705564 · Midazolam

Start the discussion